#BLTE hashtag - Bluesky

Belite Bio Reports Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update Following positive topline results from the pivotal, global Phase 3 DRAGON trial of tinlarebant in adolescents with Stargardt disease type 1 (STGD1), the Company is on track to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in Q2 2026 Completed enrollment in the

1 month ago

#BLTE Belite Bio Reports Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

www.stocktitan.net/news/BLTE/belite-bio-rep...

0 0 0 0

4 months ago

News; ( NASDAQ: #BLTE ) BLTE Price Target Alert: $200.00. Issued by Maxim Group

0 0 0 0

Leading Indicators, Tuesday December 2, 2025 – Crystal Equity Research

4 months ago

Small-cap stocks with strong volume declines, Tue Dec 2nd - #BGLC #CDLR #ABTC #EPOW #BLTE #HKIT #DBVT #NIVF #DOGZ #RYOJ #FTEL #SDH #GIBO #WOK #JAGX #SONN #YKDG - More: crystalequityresearch.com/leading-indi... - #smallcap

0 0 0 0

4 months ago

News; ( NASDAQ: #BLTE ) BLTE Price Target Alert: $194.00. Issued by Mizuho Securities

0 0 0 0

4 months ago

News; ( NASDAQ: #BLTE ) BLTE Price Target Alert: $185.00. Issued by H.C. Wainwright

0 0 0 0

Belite Bio Announces Pricing of $350.0 Million Underwritten Public Offering of American Depositary Shares Belite Bio (NASDAQ: BLTE) priced an underwritten public offering of 2,272,727 ADSs at $154.00 per ADS, with gross proceeds expected to be approximately $350.0 million before underwriting discounts, commissions and expenses. The company granted underwriters a 30-day option to purchase up to 340,909 additional ADSs. Closing is expected on or about December 3, 2025, subject to customary closing conditions.Belite said it intends to use net proceeds for commercialization preparation, pipeline development and working capital. Joint active book-runners include Morgan Stanley, Leerink Partners, BofA Securities and Cantor; H.C. Wainwright is lead manager.

4 months ago

#BLTE Belite Bio Announces Pricing of $350.0 Million Underwritten Public Offering of American Depositary Shares

www.stocktitan.net/news/BLTE/belite-bio-ann...

0 0 0 0

4 months ago

Breaking News: ( NASDAQ: #BLTE ) Buy Recommendation Issued On BLTE By H.C. Wainwright

0 0 0 0

Leading Indicators, Monday December 1, 2025 – Crystal Equity Research

4 months ago

Small-cap stocks with strong volume gains, Mon Dec 1st - #WBUY #SUNS #JFBR #HKIT #GLBS #FLYE #ARTL #WHLR #STTK #QTTR #VEEE #KALA #IRBT #FTEL #DRCT #CNCK #BLTE #LEG #CYH #BALY - More: crystalequityresearch.com/leading-indi... - #smallcap

0 0 0 0

Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares Belite Bio (NASDAQ: BLTE) announced on December 1, 2025 that it has commenced an underwritten public offering of American Depositary Shares (ADSs), with all offered securities to be sold by the company.The company said it will grant underwriters a 30-day option to buy additional ADSs and that the offering is subject to market conditions. Net proceeds are intended for commercialization preparation, pipeline development and working capital. Joint book-running managers include Morgan Stanley, Leerink Partners, BofA Securities and Cantor. The offering will be made only by a prospectus supplement to the company’s Form F-3ASR registration statement.

4 months ago

#BLTE Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares

www.stocktitan.net/news/BLTE/belite-bio-ann...

0 0 0 0

4 months ago

#BLTE Belite Bio Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

www.stocktitan.net/news/BLTE/belite-bio-rep...

0 0 0 0

6 months ago

Charts of the Day - small-cap stocks forming bearish engulfing candlestick signal, Mon Sept 15th - #CBAN #BLTE - More: crystalequityresearch.com/charts-of-th... - #smallcap

0 0 0 0

First-Ever Phase 3 Trial for Stargardt Disease: Belite Bio's Tinlarebant Could Be Breakthrough Treatment Biotech completes Phase 3 DRAGON trial of Tinlarebant in 104 adolescents across 11 countries. Topline data due Q4 2025, FDA filing planned 1H 2026. Drug holds multiple regulatory designations.

6 months ago

#BLTE Belite Bio Announces Completion of DRAGON, a 2-Year, Phase 3 Trial of Oral Tinlarebant in the Treatment of Stargardt Disease

www.stocktitan.net/news/BLTE/belite-bio-ann...

0 0 0 0

Belite Bio Announces Up to $275 Million Upsized Private Placement Financing by Leading Healthcare Investors Transaction led by RA Capital Management with participation from Eventide Asset Management, Marshall Wace, RTW Investments, Soleus Capital and Vestal Point Capital $125 million financing upfront with up to an additional $150 million tied to exercise of warrants Warrants exercisable at a 20% premium

6 months ago

#BLTE Belite Bio Announces Up to $275 Million Upsized Private Placement Financing by Leading Healthcare Investors

www.stocktitan.net/news/BLTE/belite-bio-ann...

0 0 0 0

Belite Bio Reports Second Quarter 2025 Financial Results and Provides a Corporate Update Belite Bio (NASDAQ: BLTE) reported Q2 2025 financial results and provided significant updates on its clinical programs. The company achieved two major milestones: FDA Breakthrough Therapy Designation for Tinlarebant in treating Stargardt disease (STGD1) and completion of enrollment with 529 subjects in the Phase 3 PHOENIX trial for geographic atrophy (GA).Financial highlights include a net loss of $16.3 million for Q2 2025, with $149.2 million in cash and equivalents. The company recently raised $15 million through a registered direct offering. R&D expenses increased to $11.0 million, up from $9.1 million in Q2 2024, while G&A expenses rose to $6.5 million from $1.4 million.The DRAGON trial for STGD1 is expected to complete by Q4 2025, following positive DSMB recommendations for trial continuation.

7 months ago

#BLTE Belite Bio Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

www.stocktitan.net/news/BLTE/belite-bio-rep...

0 0 0 0

Belite Bio Announces Registered Direct Offering of $15 Million Belite Bio, Inc ("BLTE" or the "Company") (Nasdaq: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases

7 months ago

#BLTE Belite Bio Announces Registered Direct Offering of $15 Million

www.stocktitan.net/news/BLTE/belite-bio-ann...

0 0 0 0

Leading Indicators, Thursday July 31, 2025 – Crystal Equity Research

8 months ago

Small-cap stocks in new uptrend with AROON Oscillator, Thu Jul 31st - #XTIA #SNGX #PSHG #UDMY #SRTS #MDXG #DSGR #WLDS #CLMB #BLTE #ABUS #HYAC #SPH #ETD #ANVS - More: crystalequityresearch.com/leading-indi... - #smallcap

0 0 0 0

Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy Belite Bio (NASDAQ: BLTE) has announced the completion of enrollment in its pivotal global Phase 3 PHOENIX trial evaluating Tinlarebant for geographic atrophy (GA) in dry age-related macular degeneration (AMD). The trial has successfully enrolled 500 subjects across multiple countries including the United States, United Kingdom, France, Czech Republic, Switzerland, China, Taiwan, and Australia.The 24-month, randomized, double-masked, placebo-controlled, multicenter study aims to evaluate the safety and tolerability of Tinlarebant and its potential to reduce atrophic lesion growth rate in GA patients. The United States led enrollment numbers, highlighting strong interest in the oral treatment option compared to existing invasive alternatives.This milestone is particularly significant as there are currently no approved oral treatments for GA, which is an advanced stage of dry AMD causing progressive vision loss through expanding lesions in the retina. The company plans to share interim results at the trial's midpoint.

9 months ago

#BLTE Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy

www.stocktitan.net/news/BLTE/belite-bio-ann...

0 0 0 0

BLTE - Belite Bio, Inc Latest Stock News & Market Updates Belite Bio (BLTE) news hub: Track clinical trials, drug developments & regulatory updates for retinal diseases and metabolic disorder treatments. Official source.

10 months ago

#BLTE Belite Bio Announces FDA Granting of Breakthrough Therapy Designation for Tinlarebant for the Treatment of Stargardt Disease

www.stocktitan.net/news/BLTE/belite-bio-ann...

0 0 0 0

Belite Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update Belite Bio (NASDAQ: BLTE) reported Q1 2025 financial results and provided updates on its clinical programs. The company's pivotal Phase 3 DRAGON trial for Tinlarebant in Stargardt disease (STGD1) received positive DSMB recommendation to proceed without modifications, with completion expected in Q4 2025. The PHOENIX trial for geographic atrophy has enrolled 464 of 500 targeted subjects. Financially, Belite raised $15 million through a registered direct offering in February 2025. The company reported $157.4 million in cash and equivalents, with Q1 2025 R&D expenses of $9.4 million (up from $6.8M in Q1 2024) and G&A expenses of $6.1 million (up from $1.6M). Net loss widened to $14.3 million compared to $7.9 million in the same period last year.

10 months ago

#BLTE Belite Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/BLTE/belite-bio-rep...

0 0 0 0

Just Released: Belite Bio 2024 Annual Report Reveals Full Year Performance Access Belite Bio's comprehensive 2024 Form 20-F annual report with audited financials. Download instantly from belitebio.com or request a free printed copy.

1 year ago

#BLTE Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website

www.stocktitan.net/news/BLTE/belite-bio-ann...

0 0 0 0

Belite Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update Belite Bio (NASDAQ: BLTE) has reported its Q4 and full-year 2024 financial results. The company's Phase 3 DRAGON trial for Stargardt 1 (STGD1) treatment received DSMB recommendation to proceed without modifications, with completion expected in Q4 2025. The PHOENIX trial for geographic atrophy has enrolled 406 subjects.Key financial highlights: Cash position of $31.7 million as of December 31, 2024, with additional $113.5 million in investments. The company raised $15 million through a registered direct offering in February 2025. Full-year 2024 results showed R&D expenses of $29.9 million (up from $24.8M in 2023) and G&A expenses of $10.1 million (up from $6.8M in 2023). Net loss for 2024 was $36.1 million or ($1.18) per share.Tinlarebant, their lead drug candidate, is advancing in multiple trials including the DRAGON trial for STGD1 and PHOENIX trial for geographic atrophy. The drug has received Fast Track, Rare Pediatric Disease, and Orphan Drug Designations in various regions.

1 year ago

#BLTE Belite Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

www.stocktitan.net/news/BLTE/belite-bio-rep...

0 0 0 0

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

1 year ago

Small-cap stocks with improving money flow, Tue Mar 11th - #UFCS #ZVRA #RGR #TSVT #SLRN #RANI #QURE #PFC #MMLP #INBX #CRVO #BLTE - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

Belite Bio Announces Interim Analysis Results from the Pivotal Global Phase 3 DRAGON trial of Tinlarebant in Adolescent Stargardt Disease Subjects Belite Bio (NASDAQ: BLTE) announced interim analysis results from its pivotal Phase 3 DRAGON trial of Tinlarebant in adolescent Stargardt disease patients. The Data Safety Monitoring Board (DSMB) recommended trial continuation without modifications, maintaining the original 104-subject sample size. The trial is expected to complete by Q4 2025.Key findings show that Tinlarebant is well-tolerated with a consistent safety profile. Visual acuity remained stable in most subjects, with mean changes from baseline of less than three letter scores under both standard and low luminance throughout the two-year study.The DRAGON trial is a randomized, double-masked, placebo-controlled study across 11 jurisdictions, with 2:1 randomization (active:placebo). The primary endpoint measures atrophic lesion growth rate. Tinlarebant has received multiple regulatory designations, including Fast Track and Rare Pediatric Disease in the U.S., Orphan Drug status in the U.S., Europe, and Japan, and Pioneer Drug Designation in Japan for Stargardt disease, which currently has no approved treatments.

1 year ago

#BLTE Belite Bio Announces Interim Analysis Results from the Pivotal Global Phase 3 DRAGON trial of Tinlarebant in Adolescent Stargardt Disease Subjects

www.stocktitan.net/news/BLTE/belite-bio-ann...

0 0 0 0

Belite Bio Raises Fresh Capital: $30M Total Potential as Clinical Programs Advance Belite Bio announces $15M registered direct offering at $58.07 per ADS with matching warrants, potential for additional $15M. Funding targets working capital and corporate growth.

1 year ago

#BLTE Belite Bio Announces Registered Direct Offering of $15 Million

www.stocktitan.net/news/BLTE/belite-bio-ann...

0 0 0 0